Japan

Poxel posts phase 3 diabetes data ahead of approval decision
Poxel posts phase 3 diabetes data ahead of approval decision
Fierce Biotech
Poxel
diabetes
clinical trials
imeglimin
Japan
Flag link:
Moderna in Talks to Sell 40 Million Coronavirus Vaccine Doses to Japan
Moderna in Talks to Sell 40 Million Coronavirus Vaccine Doses to Japan
Motley Fool
Moderna Therapeutics
Japan
Takeda
vaccines
COVID-19
Flag link:
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Takeda offers Japanese sales, admin staffers early retirement in post-Shire slimdown
Fierce Pharma
Takeda
Japan
early retirement
Shire
M&A
Flag link:
FDA gives speedy approval to another Duchenne drug
FDA gives speedy approval to another Duchenne drug
BioPharma Dive
FDA
NS Pharma
Japan
Duchenne Muscular Dystrophy
Viltepso
viltolarsen
Flag link:
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan
Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan
Motley Fool
Novavax
Japan
vaccines
Takeda
COVID-19
NVX-CoV2373
Flag link:
Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan
Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan
MedCity News
Pfizer
BioNTech
Japan
vaccines
COVID-19
Flag link:
Teva, Takeda offload generics, manufacturing plant to Nichi-Iko in Japanese venture reshuffle
Teva, Takeda offload generics, manufacturing plant to Nichi-Iko in Japanese venture reshuffle
Fierce Pharma
Teva Pharmaceutical
Takeda
Japan
generics
drug manufacturing
Flag link:
Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan
Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan
Pharmaforum
Eisai
Dayvigo
Japan
insomnia
Merck
Belsomra
Flag link:
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
Pharmaforum
GSK
anemia
chronic kidney disease
daprodustat
Japan
Astellas
Kyowa Kirin
Flag link:
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
Fierce Pharma
AstraZeneca
Daiichi Sankyo
University of Oxford
vaccines
COVID-19
Japan
Flag link:
Sosei pens inflammatory and autoimmune disease drug pact with AbbVie
Sosei pens inflammatory and autoimmune disease drug pact with AbbVie
Fierce Biotech
Sosei Heptares
AbbVie
Japan
drug discovery
Flag link:
Takeda posts surprise profit a year after Shire mega-merger
Takeda posts surprise profit a year after Shire mega-merger
Pharmaforum
Japan
Takeda
Shire
M&A
earnings
Flag link:
Japan approves Gilead Sciences' remdesivir as COVID-19 drug
Japan approves Gilead Sciences' remdesivir as COVID-19 drug
Reuters
Japan
Gilead Sciences
COVID-19
remdesivir
Flag link:
Gilead's COVID-19 hopeful remdesivir may get swift Japanese approval: report
Gilead's COVID-19 hopeful remdesivir may get swift Japanese approval: report
Fierce Biotech
Japan
Gilead Sciences
remdesivir
COVID-19
Flag link:
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout
Endpoints
Esperion
Nexletol
Nexlizet
Japan
cholesterol
Flag link:
White House pressures FDA on unproven Japanese drug
White House pressures FDA on unproven Japanese drug
Politico
Donald Trump
White House
COVID-19
FDA
Avigan
Fujifilm
Japan
Flag link:
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
In two-man race with Novartis, Merck scores first regulatory approval for targeted lung cancer drug
Endpoints
Novartis
Merck KGaA
Japan
tepotinib
non-small cell lung cancer
Flag link:
Japanese Flu Drug ‘Effective’ Against Coronavirus In Clinical Trials, Chinese Officials Say
Japanese Flu Drug ‘Effective’ Against Coronavirus In Clinical Trials, Chinese Officials Say
Forbes
COVID-19
Japan
China
favipiravir
Avigan
Fujifilm Toyama
clinical trials
Flag link:
Empty AstraZeneca plant sized up by CDMO which may or may not be AGC Biologics
Empty AstraZeneca plant sized up by CDMO which may or may not be AGC Biologics
Fierce Pharma
AstraZeneca
Colorado
Japan
AGC Biologics
drug manufacturing
CDMO
Flag link:

Pages